{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:42:39Z","timestamp":1789940559321,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.humpath.2019.04.002","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T23:18:56Z","timestamp":1555543136000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["MDM2 copy number increase: a poor prognostic, molecular event in esophageal squamous cell carcinoma"],"prefix":"10.1016","volume":"89","author":[{"given":"Ryuichiro","family":"Sawada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Oshikiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kakeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2019.04.002_bb0005","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2019.04.002_bb0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","article-title":"Global incidence of oesophageal cancer by histological subtype in 2012","volume":"64","author":"Arnold","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.humpath.2019.04.002_bb0015","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/2159-8290.CD-12-0189","article-title":"Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma","volume":"2","author":"Agrawal","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.humpath.2019.04.002_bb0020","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMra035010","article-title":"Esophageal cancer","volume":"349","author":"Enzinger","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2019.04.002_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.radonc.2007.03.013","article-title":"A randomised trial of radiotherapy compared with cisplatin chemo-radiotherapy in patients with unresectable squamous cell cancer of the esophagus","volume":"83","author":"Kumar","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.gastro.2017.06.066","article-title":"Genomic and epigenomic aberrations in esophageal squamous cell carcinoma and implications for patients","volume":"154","author":"Lin","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humpath.2019.04.002_bb0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature13176","article-title":"Identification of genomic alterations in oesophageal squamous cell cancer","volume":"509","author":"Song","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2019.04.002_bb0040","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/ng.465","article-title":"SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas","volume":"41","author":"Bass","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2019.04.002_bb0045","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ajhg.2015.12.013","article-title":"Whole-genome sequencing reveals diverse models of structural variations in esophageal squamous cell carcinoma","volume":"98","author":"Cheng","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.humpath.2019.04.002_bb0050","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1053\/j.gastro.2016.01.035","article-title":"Genomic landscape of esophageal squamous cell carcinoma in a Japanese population","volume":"150","author":"Sawada","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humpath.2019.04.002_bb0055","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/ng.2935","article-title":"Genomic and molecular characterization of esophageal squamous cell carcinoma","volume":"46","author":"Lin","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2019.04.002_bb0060","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","article-title":"The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation","volume":"69","author":"Momand","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2019.04.002_bb0065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2019.04.002_bb0070","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/375694a0","article-title":"Interaction between the retinoblastoma protein and the oncoprotein MDM2","volume":"375","author":"Xiao","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2019.04.002_bb0075","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1101\/gad.11.6.714","article-title":"Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53","volume":"11","author":"Lundgren","year":"1997","journal-title":"Genes Dev"},{"key":"10.1016\/j.humpath.2019.04.002_bb0080","doi-asserted-by":"crossref","first-page":"18771","DOI":"10.1074\/jbc.M413387200","article-title":"Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair","volume":"280","author":"Alt","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2019.04.002_bb0085","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1053\/j.gastro.2014.07.001","article-title":"Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice","volume":"147","author":"Wang","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humpath.2019.04.002_bb0090","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/nar\/26.15.3453","article-title":"The MDM2 gene amplification database","volume":"26","author":"Momand","year":"1998","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.humpath.2019.04.002_bb0095","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/modpathol.2009.149","article-title":"Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma","volume":"22","author":"Erickson-Johnson","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0100","first-page":"1077","article-title":"Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations","volume":"60","author":"Cuny","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2019.04.002_bb0105","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/jop.12394","article-title":"Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer","volume":"45","author":"Ach","year":"2016","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.humpath.2019.04.002_bb0110","first-page":"769","article-title":"p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma","volume":"1","author":"Shibagaki","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2019.04.002_bb0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0006-291X(02)00836-7","article-title":"Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH","volume":"296","author":"Ishizuka","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.humpath.2019.04.002_bb0120","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3892\/or.2016.4578","article-title":"MDM2 gene amplification in esophageal carcinoma","volume":"35","author":"Michalk","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.humpath.2019.04.002_bb0125","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1054\/bjoc.2001.1990","article-title":"TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe","volume":"85","author":"Tani\u00e8re","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2019.04.002_bb0130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","article-title":"A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)","volume":"19","author":"Ando","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0135","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.5858\/arpa.2015-0249-OA","article-title":"Automated bright-field dual-color in situ hybridization for MDM2: interobserver reproducibility and correlation with fluorescence in situ hybridization in a series of soft tissue consults","volume":"140","author":"Zhang","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2019.04.002_bb0140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/PAI.0b013e3181ee8e14","article-title":"Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas","volume":"19","author":"Zhang","year":"2011","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0145","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4048\/jbc.2012.15.4.381","article-title":"HER2 status by standardized immunohistochemistry and silver-enhanced in situ hybridization in Korean breast cancer","volume":"15","author":"Bae","year":"2012","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.humpath.2019.04.002_bb0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fonc.2016.00007","article-title":"Clinical overview of MDM2\/X-targeted therapies","volume":"6","author":"Burgess","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0155","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.humpath.2019.04.002_bb0160","doi-asserted-by":"crossref","first-page":"E3445","DOI":"10.1073\/pnas.1303002110","article-title":"Stapled \u03b1-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy","volume":"110","author":"Chang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2019.04.002_bb0165","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2019.04.002_bb0170","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2019.04.002_bb0175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ctrv.2018.07.006","article-title":"Hyperprogression as a distinct outcome after immunotherapy","volume":"70","author":"Fuentes-Antr\u00e1s","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.humpath.2019.04.002_bb0180","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2019.04.002_bb0185","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/PAS.0000000000001006","article-title":"MDM2 amplification in intrahepatic cholangiocarcinomas: its relationship with large-duct type morphology and uncommon KRAS mutations","volume":"42","author":"Kim","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0190","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1053\/ejso.1999.0658","article-title":"Amplification of cyclin D1 and MDM-2 in oesophageal carcinoma","volume":"25","author":"Morgan","year":"1999","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0195","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/1097-0215(20001015)88:2<223::AID-IJC12>3.0.CO;2-G","article-title":"TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the esophagus in South Thailand","volume":"88","author":"Tani\u00e8re","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2019.04.002_bb0200","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1158\/0008-5472.CAN-06-1951","article-title":"Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non\u2013small cell lung cancer","volume":"66","author":"Inukai","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2019.04.002_bb0205","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nature09460","article-title":"The patterns and dynamics of genomic instability in metastatic pancreatic cancer","volume":"467","author":"Campbell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2019.04.002_bb0210","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2019.04.002_bb0215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2013.103","article-title":"HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity","volume":"27","author":"Hanna","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0220","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1309\/AJCP0EN6AQMWETZZ","article-title":"Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition","volume":"136","author":"Bartlett","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0225","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.tig.2006.06.007","article-title":"Gene amplification in cancer","volume":"22","author":"Albertson","year":"2006","journal-title":"Trends Genet"},{"key":"10.1016\/j.humpath.2019.04.002_bb0230","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/01.pas.0000165528.78945.95","article-title":"The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study","volume":"29","author":"Downs-Kelly","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0235","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1200\/JCO.2007.13.4296","article-title":"Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing","volume":"26","author":"Vanden Bempt","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0240","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.2574","article-title":"Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis","volume":"219","author":"Marchi\u00f2","year":"2009","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2019.04.002_bb0245","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1535-7163.MCT-06-0129","article-title":"Correction for chromosome-17 is critical for the determination of true Her-2\/neu gene amplification status in breast cancer","volume":"5","author":"Dal Lago","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.humpath.2019.04.002_bb0250","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771930067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771930067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T04:06:13Z","timestamp":1563249973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681771930067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":50,"alternative-id":["S004681771930067X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2019.04.002","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MDM2 copy number increase: a poor prognostic, molecular event in esophageal squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2019.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}